More radionuclide therapy is better for prostate cancer patients

November 1, 2011 in Cancer

For prostate cancer patients with bone metastases, repeated administrations of radionuclide therapy with 188Re-HEDP are shown to improve overall survival rates and reduce pain, according to new research published in the November issue of The Journal of Nuclear Medicine.

Approximately 50 percent of prostate cancer patients develop that are predominately osteoblastic, that is, have the tendency to fracture resulting in serious morbidity. This type of often leads to chronic pain syndrome in prostate cancer patients; as many as 50 percent of prostate cancer patients with chronic pain syndrome are reported to receive inadequate pain treatment, which makes them candidates for radionuclide therapy.

The retrospective study, "Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A ," reviewed cases of 60 patients with hormone-refractory prostate cancer. The patients, all of whom had more than five lesions documented by a bone scan, were divided into three groups—those who received one therapy, two therapies or three or more therapies.

"Radionuclide therapy of bone metastases has been used for several decades for those with prostate cancer," noted lead author of the study Hans-Juergen Biersack, MD. "For this study, we developed 188Re-HEDP as a novel radiopharmaceutical which—due to it is short half life of 19 hours—makes sequential therapy possible."

The researchers found that post-treatment survival increased with the number of radionuclide therapies administered. Patients with progressive hormone-refractory prostate cancer receiving one therapy added 4.5 months, those receiving two therapies added 10 months, and those receiving three or more therapies improved their survival by 15.7 months. In addition, while the Gleason scores—a grading system used to evaluate the prognosis of men with —for each group were similar, the number of life-lost years for patients receiving three or more therapies was significantly lower.

In regards to pain reduction, no significant difference was found among those receiving 188Re-HEDP therapies. Pain reduction was achieved in 89.5 percent of those receiving one therapy, in 94.7 percent of those receiving two therapies and in 90.9 percent of those receiving three or more therapies.

"For patients failing chemotherapy or hormone treatments, 188Re-HEDP is a promising therapy that can both extend the number of survival years and help relieve pain from bone metastases," noted Biersack. "The findings support and expand the role of molecular therapy with radioisotopes in oncology."

188Re-HEDP is not commercially available and in-house production is required. 188Re-HEDP treatments for this study were developed at Oak Ridge National Laboratory in Oak Ridge, Tenn.

More information: "Palliation and Survival After Repeated 188Re-HEDP Therapy of Hormone-Refractory Bone Metastases of Prostate Cancer: A Retrospective Analysis", Journal of Nuclear Medicine.

Provided by Society of Nuclear Medicine search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

Research identifies a way to make cancer cells more responsive to chemotherapy

Breast cancer characterized as "triple negative" carries a poor prognosis, with limited treatment options. In some cases, chemotherapy doesn't kill the cancer cells the way it's supposed to. New research from Western University ...

Cancer created 2 hours ago | popularity 5 / 5 (2) | comments 0

Mayo Clinic genomic analysis lends insight to prostate cancer

Mayo Clinic researchers have used next generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings ...

Cancer created 2 hours ago | popularity not rated yet | comments 0

When oxygen is short, EGFR prevents maturation of cancer-fighting miRNAs

Even while being dragged to its destruction inside a cell, a cancer-promoting growth factor receptor fires away, sending signals that thwart the development of tumor-suppressing microRNAs (miRNAs) before it's dissolved, researchers ...

Cancer created 3 hours ago | popularity not rated yet | comments 0 | with audio podcast

Improved chemo regimen for childhood leukemia may offer high survival, no added heart toxicity

Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at a more intense-than-standard dose during initial treatment may result in high survival rates without causing any added ...

Cancer created 7 hours ago | popularity not rated yet | comments 0

Protein preps cells to survive stress of cancer growth and chemotherapy

Scientists have uncovered a survival mechanism that occurs in breast cells that have just turned premalignant-cells on the cusp between normalcy and cancers-which may lead to new methods of stopping tumors.

Cancer created 8 hours ago | popularity not rated yet | comments 0 | with audio podcast


Glucosamine supplements tied to risk of eye condition

(HealthDay)—Glucosamine supplements that millions of Americans take to help treat hip and knee osteoarthritis may have an unexpected side effect: They may increase risk for developing glaucoma, a small ...

Controlling mood through the motions of mitochondria

(Medical Xpress)—Regulating the distribution of power in neurons is done by a system that makes the national electric grid look simple by comparison. Each neuron has several thousand mitochondria confined ...

Scientists discover molecule triggers sensation of itch

Scientists at the National Institutes of Health report they have discovered in mouse studies that a small molecule released in the spinal cord triggers a process that is later experienced in the brain as ...

Multiple research teams unable to confirm high-profile Alzheimer's study

Teams of highly respected Alzheimer's researchers failed to replicate what appeared to be breakthrough results for the treatment of this brain disease when they were published last year in the journal Science.

Researchers find common childhood asthma unconnected to allergens or inflammation

Little is known about why asthma develops, how it constricts the airway or why response to treatments varies between patients. Now, a team of researchers at Weill Cornell Medical College, Columbia University Medical Center ...

Motion quotient: IQ predicted by ability to filter motion (w/ video)

A brief visual task can predict IQ, according to a new study. This surprisingly simple exercise measures the brain's unconscious ability to filter out visual movement. The study shows that individuals whose ...